1PhD Student in School of Public Health
2Department of Medical Biochemistry Faculty of Medicine, Soetomo General Hospital
3Department of Clinical Pathology, Faculty of Medicine, Soetomo General Hospital
4Department of Nutrition, Faculty of Public Health
5Department of Fetomaternal, Faculty of Medicine, Soetomo General Hospital, Universitas Airlangga, Surabaya, Indonesia
6Department of Public Health Nutrition, Faculty of Public Health, Universitas Hasanuddin, Makassar, Indonesia
Online published on 1 November, 2018.
The role of Selenium in preventing preeclampsia has been proved in some studies. It is evident that the decrease of Selenium level results in oxidative stress in the placenta, leading to preeclampsia symptoms. This study aims to prove the effect of Selenium on women during the period of preconception to Selenium level and sFlt-1/PlGf ratio in plasma to prevent preeclampsia incidence at the molecular level.
The research will use the double blind, randomized, control trial design. The samples are women in preconception period (34 samples in each group). The intervention group will receive Selenium in MMN preparation, while the control group will receive capsules containing ferrum and folic acid (national program). During preconception period, the capsules will be given once a week, while pregnant women will be given the capsules once a day. The levels of selenium will be examined before the treatment. At the 12th and 20th weeks of pregnancy, selenium and Sflt-1, and PlGF were measured. Selenium levels will be measured statistically using the t-test pre-post and paired t-test, while the Sflt-1/PlGF ratio will be determined using a t-test to compare the two groups.
There was no difference between sFlt-1/PlGF ratio in two groups (p=0, 23) at the 12th weeks, and (p=0, 119) at the 20th weeks. Increasing of sFlt-1/PlGF ratio in IFA group higher then MMN group. Mean of sFlt-1/PlGF ratio under 38 in two groups.
This study discover the efficacy of selenium supplementation in MMN preparations given since preconception time is more effective in reducing the sFlt-1/PlGF ratio at 20 weeks of pregnancy than in group given the Iron Folate supplement and will help to uncover the critical areas of preventing preeclampsia early in molecular level that many researchers were not able to explore. Thus, a new theory on these selenium supplementation in MMN preparations, and possibly other combinations, may be arrived at.
Preconception, Selenium, MDA, Sflt-1, Preeclampsia
